Logo Image
News|Articles|July 15, 2026

From PC to CPV: Preserving Process Knowledge Through Late-Phase Tech Transfer

Author(s)Catalent

Want to know what it really takes to protect a drug substance process's scientific integrity when it moves to a new manufacturing site? This executive summary, featuring the insights of Danielle Wittenwyler, PhD, Associate Director of Process Development, Drug Substance Lifecycle at Catalent, examines how late phase tech transfer can preserve process characterization (PC) as active scientific knowledge rather than static documentation. It outlines the common sources of transfer risk and describes a risk-based approach to bridging studies. The piece explains how preserved process knowledge supports more meaningful process validation (PV) and continued process verification (CPV) throughout the product lifecycle

Related to this article

View more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more
The Promise of Microgravity for R&D and Manufacturing
The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Read more